Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 765049 in Advanced Colorectal, Gastric, or Pancreatic Cancer
NCT06882746Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2025
- Primary completion
- Sep 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of BI 765049 in colorectal carcinoma (CRC), Gastric carcinoma (GC) and pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Dose Limiting Toxicities up to 36 months. Started Mar 2025; status: terminated.
02
Drugs
BI 765049
03
Conditions
colorectal carcinoma (CRC)Gastric carcinoma (GC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06882746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06882746.